Lumos Pharma Q2 EPS $(1.09) Beats $(1.10) Estimate, Sales $527.00K Beat $410.00K Estimate
Portfolio Pulse from mahesh@benzinga.com
Lumos Pharma reported Q2 earnings per share (EPS) of $(1.09), beating the analyst consensus estimate of $(1.10) by 0.91%. This is a 15.96% decrease from the same period last year. The company also reported quarterly sales of $527.00K, beating the analyst consensus estimate of $410.00K by 28.54%. This is a 30.77% increase from the same period last year.
August 09, 2023 | 8:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lumos Pharma's Q2 earnings and sales beat analyst estimates, which could positively impact the stock in the short term.
Lumos Pharma reported better-than-expected Q2 earnings and sales, which is generally seen as a positive signal by the market and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100